Table 6 Odds ratios (ORs) for hepatocellular carcinoma (HCC) associated with persistence of sequence variants of hepatitis B virus*
Variant(At baseline/at follow-up)†HCC (n = 71) (%)Controls (n = 81) (%)OR‡ (95% CI)
nt 1703(−/−)59 (83.1)78 (96.3)1
(+/−) or (−/+)3 (4.2)2 (2.5) to
(+/+)9 (12.7)1 (1.2)12.19 (1.48 to 100.37)
nt 1719(−/−)51 (71.8)76 (93.8)1
(+/−) or (−/+)6 (8.5)3 (3.7) to
(+/+)14 (19.7)2 (2.5)10.49 (2.24 to 49.11)
nt 1726(−/−)27 (38.0)49 (60.5)1
(+/−) or (−/+)8 (11.3)13 (16.0)1.09 (0.40 to 3.02)
(+/+)36 (50.7)19 (23.5)3.60 (1.71 to 7.58)
nt 1727(−/−)29 (40.8)58 (71.6)1
(+/−) or (−/+)9 (12.7)10 (12.3)1.96 (0.69 to 5.54)
(+/+)33 (46.5)13 (16.1)6.10 (2.67 to 13.92)
nt 1730(−/−)31 (43.7)61 (75.3)1
(+/−) or (−/+)8 (11.2)10 (12.3)2.00 (0.69 to 5.81)
(+/+)32 (45.1)10 (12.3)7.42 (3.10 to 17.72)
nt 1753(−/−)45 (63.4)60 (74.1)1
(+/−) or (−/+)13 (18.3)15 (18.5)1.16 (0.50 to 2.72)
(+/+)13 (18.3)6 (7.4)2.90 (1.00 to 8.42)
BCP double(−/−)19 (26.8)40 (49.4)1
variants(+/−) or (−/+)13 (18.3)22 (27.2)1.17 (0.48 to 2.86)
(+/+)39 (54.9)19 (23.4)4.72 (2.11 to 10.57)
nt 1799(−/−)29 (40.8)54 (66.7)1
(+/−) or (−/+)8 (11.3)15 (18.5)1.12 (0.41 to 3.03)
(+/+)34 (47.9)12 (14.8)6.12 (2.66 to 14.08)
Precore start/stop codon mutation(−/−)13 (18.3)9 (11.1)1
(+/−) or (−/+)17 (23.9)18 (22.2)0.60 (0.20 to 1.79)
(+/+)41 (57.8)54 (66.7)0.54 (0.21 to 1.41)
  • *A total of 71 cases and 81 controls who had a baseline blood sample and a blood sample collected at follow-up were included in analysis.

  • †“−”: absence; “+”: presence.

  • ‡OR adjusted for age at recruitment (continuous variable) and the interval between the dates the baseline sample and the follow-up sample were collected (continuous variable).

  • CI, confidence interval; nt, nucleotide; BCP, basal core promoter.